These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 2230873

  • 21. Irradiated cells from autologous tumor cell lines as patient-specific vaccine therapy in 125 patients with metastatic cancer: induction of delayed-type hypersensitivity to autologous tumor is associated with improved survival.
    Dillman RO, Beutel LD, Barth NM, de Leon C, O'Connor AA, DePriest C, Nayak SK.
    Cancer Biother Radiopharm; 2002 Feb; 17(1):51-66. PubMed ID: 11915174
    [Abstract] [Full Text] [Related]

  • 22. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro.
    Chang AE, Yoshizawa H, Sakai K, Cameron MJ, Sondak VK, Shu S.
    Cancer Res; 1993 Mar 01; 53(5):1043-50. PubMed ID: 8439951
    [Abstract] [Full Text] [Related]

  • 23. Active specific immunotherapy of Dukes B2 and C colorectal carcinoma: comparison of two doses of the vaccine.
    Jessup JM, McBride CM, Ames FC, Guarda L, Ota DM, Romsdahl MM, Martin RG.
    Cancer Immunol Immunother; 1986 Mar 01; 21(3):233-9. PubMed ID: 2938738
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial.
    Schlag P, Manasterski M, Gerneth T, Hohenberger P, Dueck M, Herfarth C, Liebrich W, Schirrmacher V.
    Cancer Immunol Immunother; 1992 Mar 01; 35(5):325-30. PubMed ID: 1394336
    [Abstract] [Full Text] [Related]

  • 26. Lack of effect of cyclophosphamide on the immunogenicity of a melanoma antigen vaccine.
    Oratz R, Dugan M, Roses DF, Harris MN, Speyer JL, Hochster H, Weissman J, Henn M, Bystryn JC.
    Cancer Res; 1991 Jul 15; 51(14):3643-7. PubMed ID: 2065322
    [Abstract] [Full Text] [Related]

  • 27. Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: outcome of a phase I study.
    Schreiber S, Kämpgen E, Wagner E, Pirkhammer D, Trcka J, Korschan H, Lindemann A, Dorffner R, Kittler H, Kasteliz F, Küpcü Z, Sinski A, Zatloukal K, Buschle M, Schmidt W, Birnstiel M, Kempe RE, Voigt T, Weber HA, Pehamberger H, Mertelsmann R, Bröcker EB, Wolff K, Stingl G.
    Hum Gene Ther; 1999 Apr 10; 10(6):983-93. PubMed ID: 10223732
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Enhanced humoral immune response correlates with improved disease-free and overall survival in American Joint Committee on Cancer stage II melanoma patients receiving adjuvant polyvalent vaccine.
    DiFronzo LA, Gupta RK, Essner R, Foshag LJ, O'Day SJ, Wanek LA, Stern SL, Morton DL.
    J Clin Oncol; 2002 Aug 01; 20(15):3242-8. PubMed ID: 12149297
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Melanoma-reactive human cytotoxic T lymphocytes derived from skin biopsies of delayed-type hypersensitivity reactions induced by injection of an autologous melanoma cell line.
    Waanders GA, Rimoldi D, Liénard D, Carrel S, Lejeune F, Dietrich PY, Cerottini JC, Romero P.
    Clin Cancer Res; 1997 May 01; 3(5):685-96. PubMed ID: 9815737
    [Abstract] [Full Text] [Related]

  • 32. Allogeneic human liposomal melanoma vaccine with or without IL-2 in metastatic melanoma patients: clinical and immunobiological effects.
    Adler A, Schachter J, Barenholz Y, Bar LK, Klein T, Korytnaya R, Sulkes A, Michowiz R, Cohen Y, Kedar I.
    Cancer Biother; 1995 May 01; 10(4):293-306. PubMed ID: 8590895
    [Abstract] [Full Text] [Related]

  • 33. Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant.
    Mitchell MS, Kan-Mitchell J, Kempf RA, Harel W, Shau HY, Lind S.
    Cancer Res; 1988 Oct 15; 48(20):5883-93. PubMed ID: 3262416
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. [Phase II clinical trial of autologous dendritic cell vaccine with immunologic adjuvant in cutaneous melanoma patients].
    Baldueva IA, Novik AV, Moiseenko VM, Nekhaeva TL, Danilova AB, Danilov AO, Protsenko SA, Petrova TIu, Uleĭskaia GI, Shchekina LA, Semenova AI, Mikhaĭlichenko TD, Teletaeva GM, Zhabina AS, Volkov NV, Komarov IuI.
    Vopr Onkol; 2012 Oct 15; 58(2):212-21. PubMed ID: 22774527
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells.
    Lotem M, Machlenkin A, Hamburger T, Nissan A, Kadouri L, Frankenburg S, Gimmon Z, Elias O, David IB, Kuznetz A, Shiloni E, Peretz T.
    Clin Cancer Res; 2009 Aug 01; 15(15):4968-77. PubMed ID: 19602547
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). The new American Joint Committee on Cancer.
    Lotem M, Peretz T, Drize O, Gimmon Z, Ad El D, Weitzen R, Goldberg H, Ben David I, Prus D, Hamburger T, Shiloni E.
    Br J Cancer; 2002 May 20; 86(10):1534-9. PubMed ID: 12085200
    [Abstract] [Full Text] [Related]

  • 40. Specific immunotherapy with suppressor function inhibition for metastatic renal cell carcinoma.
    Sahasrabudhe DM, deKernion JB, Pontes JE, Ryan DM, O'Donnell RW, Marquis DM, Mudholkar GS, McCune CS.
    J Biol Response Mod; 1986 Dec 20; 5(6):581-94. PubMed ID: 3491881
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.